Skip to main content
Premium Trial:

Request an Annual Quote

Unilabs to Develop Companion Dx for Biogen Idec Drug

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Unilabs will develop a companion diagnostic assay for a Biogen Idec drug for patients receiving a multiple sclerosis treatment, the Copenhagen-based firm said today.

Under the agreement, Unilabs will develop a two-step ELISA test to detect anti-JCV antibodies to help stratify patients receiving Biogen Idec's Tysabri (natalizumab). The presence of anti-JCV antibodies is one of three risk factors, along with prior immunosuppressant use and treatment duration, used to calculate the risk of Tysabri-treated patients developing progressive multifocal leukoencephalopathy.

The firms have also developed a closed web interface to allow neurologists to order sampling and shipping materials, register sample pick-up details, and request language and format of analytical reports.

Further terms of the collaboration were not disclosed.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.